- A. Health Biotechnology
- Areas of activity
- Drug development
- Drug discovery
- Therapeutic areas
- Inflammatory diseases
INHIBITEC Anticuerpos S.L. is a pre clinical and clinical stage biotechnology company founded in 2019 in Santander, (Cantabria), Spain, focused on the development of a therapeutic monoclonal antibody (mAB) to be used in cure of autoimmune diseases and more specifically in Psoriasis and Psoriasic Arthritis.
Our technology is based in a patent owned by the Spanish National Research Council (CSIC) and the Universidad de Cantabria (UC), filled in 2015.
Our approach is a novel pathway to increase the efficacy vs current therapies for the treatment of Psoriasis and Psoriatic Arthritis
Our monoclonal antibody (mAb) works against BAMBI (BMP and Activin Membrane-Bound Inhibitor). BAMBI is a transmembrane molecule that inhibits a key signal pathway that controls two lymphoid subpopulations with opposed roles in the pathogenesis of autoimmune diseases.
Immunotherapies; Non clinical and clinical studies; dermatological and rheumatic diseases